2021 AACR: Bayer plans to announce iNHL Phase III clinical data and its...

Compileriver

On April 6, according to foreign media reports, Bayer plans to present its new research in the field of oncology at the 2021 Virtual American Association for Cancer Research (AACR) annual meeting.

In 2017, based on the results of a single-arm, multi-center, phase II clinical trial of CHRONOS-1, Aliqopa was approved for the treatment of adult patients with recurrent follicular lymphoma (FL) who had received at least two systemic treatments before.

At this meeting, Bayer will also present relevant data on biomarker-driven therapy.

Vitrakvi is approved for the treatment of adult and pediatric solid tumor patients who carry NTRK fusion gene but have no known acquired mutations, metastasis or surgical resection may lead to serious diseases, and who do not have satisfactory alternative treatments or progress after treatment.

This time, the company will also report on the prostate cancer research of NUBEQA® (darolutamide) for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).

NUBEQA is an androgen receptor inhibitor (ARi) with a unique chemical structure that can competitively inhibit androgen binding, AR nuclear translocation and AR-mediated transcription.

Bayer will also release the latest data on its differentiated early-stage pipelines in other key areas, including precision molecular oncology and immuno-oncology.

Reference source: Bayer to Present New Clinical Data in Indolent non-Hodgkin's Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021